TY - JOUR
T1 - Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure
AU - Schmitt, M
AU - Gunaruwan, P
AU - Payne, N
AU - Taylor, J
AU - Lee, L
AU - Broadley, AJ
AU - Nightingale, AK
AU - Cockcroft, JR
AU - Struthers, AD
AU - Tyberg, JV
AU - Frenneaux, Michael
PY - 2004/1/1
Y1 - 2004/1/1
N2 - OBJECTIVE: Natriuretic peptides (NPs) reduce central venous pressure in patients with chronic heart failure (cHF) despite attenuation of arterial, renal, and humoral effects. This suggests a preserved venodilator response. This study had 4 aims: to compare the venodilator effects of human NPs in patients with cHF; to assess the contribution of basal ANP and BNP levels to regulation of forearm vascular volume (FVV); to test the hypothesis that venous ANP responsiveness is preserved in cHF; and to assess the involvement of endothelial nitric oxide-synthase (eNOS) in NP-induced vascular effects. METHODS AND RESULTS: Venous and arterial forearm vascular responses to incremental intra-arterial doses of ANP, Urodilatin, BNP, CNP, or the ANP receptor antagonist A71915 were studied in 53 patients and 11 controls. ANP receptor antagonism reduced FVV by 4.4%+/-1.2% (P
AB - OBJECTIVE: Natriuretic peptides (NPs) reduce central venous pressure in patients with chronic heart failure (cHF) despite attenuation of arterial, renal, and humoral effects. This suggests a preserved venodilator response. This study had 4 aims: to compare the venodilator effects of human NPs in patients with cHF; to assess the contribution of basal ANP and BNP levels to regulation of forearm vascular volume (FVV); to test the hypothesis that venous ANP responsiveness is preserved in cHF; and to assess the involvement of endothelial nitric oxide-synthase (eNOS) in NP-induced vascular effects. METHODS AND RESULTS: Venous and arterial forearm vascular responses to incremental intra-arterial doses of ANP, Urodilatin, BNP, CNP, or the ANP receptor antagonist A71915 were studied in 53 patients and 11 controls. ANP receptor antagonism reduced FVV by 4.4%+/-1.2% (P
UR - http://www.scopus.com/inward/record.url?scp=2442559304&partnerID=8YFLogxK
U2 - 10.1161/01.ATV.zhq0504.7914
DO - 10.1161/01.ATV.zhq0504.7914
M3 - Article
C2 - 15001459
SN - 1524-4636
SN - 1524-4636
SN - 1524-4636
SN - 1524-4636
SN - 1524-4636
SN - 1524-4636
SN - 1524-4636
SN - 1524-4636
SN - 1524-4636
SN - 1524-4636
SN - 1524-4636
SN - 1524-4636
VL - 24
SP - 911
EP - 917
JO - Arteriosclerosis Thrombosis and Vascular Biology
JF - Arteriosclerosis Thrombosis and Vascular Biology
ER -